SCHEMBL242207

SCHEMBL242207

Cc1ccc(S(=O)(=O)OC(C)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.47
GAA P10253 4/20 0.46
CA2 P00918 3/20 0.43
CA1 P00915 2/20 0.43
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA3 P07451 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
VDR P11473 1/20 0.42
TLR9 Q9NR96 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 3/20 0.40
GBA1 P04062 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29224493 0.86 AGER (0.46) AGERGAACA2CA1CA12
SCHEMBL872063 0.86 AGER (0.48) AGERGAACA2CA1CA12
SCHEMBL17350536 0.85 AGER (0.42) AGERGAACA2CA1CA12
SCHEMBL5557903 0.85 GAA (0.52) AGERGAACA2CA1CA12
SCHEMBL2342945 0.85 GAA (0.52) AGERGAACA2CA1CA12
SCHEMBL143705 0.83 GAA (0.50) AGERGAACA2CA1CA12
SCHEMBL890642 0.83 GAA (0.50) AGERGAACA2CA1CA12
SCHEMBL1414705 0.82 AGER (0.46) AGERGAACA2CA1CA12
SCHEMBL4671544 0.82 GBA1 (0.42) AGERGAACA2CA1CA12
SCHEMBL9711306 0.82 AGER (0.42) AGERGAACA2CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865858-A Novel PET imaging agent targeting cannabinoid type 2 receptor, preparation method and application thereof 浙江大学 2024-04-12 CN claimed
CN-117199523-A Electrolyte, secondary battery and electric equipment 欣旺达动力科技股份有限公司 2023-12-08 CN claimed
US-11242314-B2 Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride WASHINGTON UNIVERSITY (US) 2022-02-08 US claimed
CN-111233834-B FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers 北京师范大学 2021-08-31 CN claimed
US-20170197912-A1 SYNTHESIZING PET TRACERS USING [F-18]SULFONYL FLUORIDE AS A SOURCE OF [F-18]FLUORIDE WASHINGTON UNIVERSITY (US) 2017-07-13 US claimed
US-20150367005-A1 METHOD OF SYNTHESIZING FLUORINE-18 LABELED RADIOPHARMACEUTICALS IN ETHANOL AND WATER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-12-24 US claimed
WO-2008132211-A1 AMINO-QUINAZOLINONE DERIVATIVES FOR USE AS RADIOTRACERS AND IMAGING AGENTS NOVARTIS AG (CH) 2008-11-06 WO claimed
EP-4680596-A1 FLUORINATED MU-OPIOID RECEPTOR AGONISTS The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2026-01-21 EP disclosed
WO-2024196438-A9 FLUORINATED MU-OPIOID RECEPTOR AGONISTS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-11-13 WO disclosed
US-20250339566-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN UNIV ANTWERPEN (BE) 2025-11-06 US disclosed
US-12324845-B2 Ligands for imaging cardiac innervation LANTHEUS MEDICAL IMAGING, INC. (US) 2025-06-10 US disclosed
US-20250161500-A1 LIGANDS FOR IMAGING CARDIAC INNERVATION LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-22 US disclosed
WO-2025085387-A1 SUBSTITUTED-ALKENYL-INDAZOLES FOR IMAGING AGGREGATED TAU IN TAUOPATHIES UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-04-24 WO disclosed
US-20030158460-A1 Radiolabeled solid surfaces and process for making them BAR-ILAN UNIVERSITY (IL) 2003-08-21 US disclosed
EP-1096934-A1 OXAZOLIDINONES TO TREAT EYE INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2001-05-09 EP disclosed
EP-1083900-A2 TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY PHARMACIA & UPJOHN COMPANY (US) 2001-03-21 EP disclosed
WO-2000003710-A1 OXAZOLIDINONES TO TREAT EYE INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2000-01-27 WO disclosed
WO-1999062504-A2 TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY PHARMACIA & UPJOHN COMPANY (US) 1999-12-09 WO disclosed
EP-0882041-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 1998-12-09 EP disclosed
WO-1997027188-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ZENECA LIMITED (GB) 1997-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197912-A1 SYNTHESIZING PET TRACERS USING [F-18]SULFONYL FLUORIDE AS A SOURCE OF [F-18]FLUORIDE STX18, GPR119, SLC5A1 AGER 532/4885GAA 268/4885CA2 818/4885
US-11242314-B2 Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride STX18, GPR119, SLC5A1 AGER 532/4885GAA 268/4885CA2 818/4885
US-20150367005-A1 METHOD OF SYNTHESIZING FLUORINE-18 LABELED RADIOPHARMACEUTICALS IN ETHANOL AND WATER TMEM14C, ADH1A, SELENOI AGER 3342/4885GAA 1392/4885CA2 2348/4885
US-20250339566-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FIBP, FGF1, FGFR1 AGER 1576/4885GAA 766/4885CA2 362/4885
US-20250161500-A1 LIGANDS FOR IMAGING CARDIAC INNERVATION TNNT2, PNMT, TNNC1 AGER 703/4885GAA 2929/4885CA2 3921/4885
US-12324845-B2 Ligands for imaging cardiac innervation CHRNB4, RXFP4, RXFP3 AGER 1382/4885GAA 4426/4885CA2 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.